Bupropion HCL ER(SR)

FDA Drug Profile — Bupropion HCL ER(SR)

Bupropion HCL ER(SR) is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Bupropion HCL ER(SR). Available dosage form: tablet, extended release.

Drug details

Generic Name
Bupropion HCL ER(SR)
Brand Names
Bupropion HCL ER(SR)
Application Number
ANDA216800
Sponsor
DriectRx
NDC Codes
2
Dosage Forms
TABLET, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
BUPROPION HYDROCHLORIDE

Indications and Usage

Bupropion hydrochloride extended-release tablets (SR) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies (14)]. The efficacy of bupropion hydrochloride extended-release tablets (SR) in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial [see Clinical Studies (14)].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.